{"id":"ide196","safety":{"commonSideEffects":[{"rate":"30%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3982723","moleculeType":"Small molecule","molecularWeight":"472.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IDE196 is a potent and selective inhibitor of MEK1/2, which are key regulators of the MAPK signaling pathway. Inhibition of MEK1/2 has been shown to be effective in treating various cancers.","oneSentence":"Selective inhibitor of MEK1/2","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:58.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05907954","phase":"PHASE2","title":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-07-03","conditions":"Uveal Melanoma","enrollment":160},{"nctId":"NCT07015190","phase":"PHASE3","title":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2026-01-25","conditions":"Uveal Melanoma","enrollment":520},{"nctId":"NCT05987332","phase":"PHASE2, PHASE3","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-10-31","conditions":"Metastatic Uveal Melanoma","enrollment":420},{"nctId":"NCT03947385","phase":"PHASE1, PHASE2","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2019-06-28","conditions":"Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Darovasertib","Protein Kinase C (PKC) Inhibitor"],"phase":"phase_2","status":"active","brandName":"IDE196","genericName":"IDE196","companyName":"IDEAYA Biosciences","companyId":"ideaya-biosciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selective inhibitor of MEK1/2 Used for Non-small cell lung cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}